Mounjaro® (Tirzepatide) — Advanced Blood Sugar and Weight Management
Innovative Treatment for Type 2 Diabetes
Mounjaro® (Tirzepatide) is the first and only FDA-approved medication that targets both GIP and GLP-1 receptors, providing enhanced blood sugar control and significant weight loss benefits. This once-weekly injectable treatment is designed to regulate insulin levels, slow digestion, reduce appetite, and support long-term metabolic health.
As a trusted medicine wholesaler in Delhi, A.K. Pharma supplies genuine Mounjaro (Tirzepatide) to hospitals, nursing homes, clinics, and pharmacies across India. Manufactured by Eli Lilly and Company, one of the world’s leading pharmaceutical companies, Mounjaro represents a breakthrough in the treatment of Type 2 diabetes.
What is Mounjaro (Tirzepatide)?
Mounjaro contains Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike traditional GLP-1 medications such as Ozempic (Semaglutide), Mounjaro activates two different hormone receptors simultaneously, making it more effective at controlling blood sugar and supporting weight loss than single-receptor treatments.
Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. It is available as a pre-filled injection pen for convenient once-weekly self-administration.
Full prescribing information is available at the FDA label for Tirzepatide.
Clinical Studies and Evidence
Mounjaro’s effectiveness is backed by the SURPASS clinical trial programme — one of the largest and most comprehensive Type 2 diabetes trial programmes ever conducted.
SURPASS-1 (Tirzepatide Monotherapy) Published in the New England Journal of Medicine (2021), the SURPASS-1 trial showed that Tirzepatide reduced HbA1c by up to 2.11% compared to placebo, with significant weight loss across all doses.
SURPASS-2 (Tirzepatide vs Semaglutide) Published in the New England Journal of Medicine (2021), the SURPASS-2 trial directly compared Tirzepatide to Semaglutide 1mg. Tirzepatide at 15mg achieved an HbA1c reduction of 2.46% vs 1.86% for Semaglutide, and weight loss of 13.1kg vs 6.2kg.
SURPASS-3 (Tirzepatide vs Insulin Degludec) Results showed Tirzepatide achieved superior glycemic control and significant weight loss compared to insulin degludec, with a 2.37% HbA1c reduction at the highest dose.
SURMOUNT-1 (Weight Management) Published in the New England Journal of Medicine (2022), the SURMOUNT-1 trial showed Tirzepatide at 15mg achieved an average body weight reduction of 22.5% in adults with obesity or overweight.
SURPASS-CVOT (Cardiovascular Outcomes) The ongoing cardiovascular outcomes trial is evaluating Mounjaro’s effect on major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and established cardiovascular disease.
Available Strengths
Mounjaro is available in the following strengths:
- 2.5mg injection pen
- 5mg injection pen
- 7.5mg injection pen
- 10mg injection pen
- 12.5mg injection pen
- 15mg injection pen
Each pen contains a single dose for subcutaneous injection once per week. Treatment typically starts at 2.5mg per week and is gradually increased based on patient response and tolerability.
Key Benefits of Mounjaro
Improves Blood Sugar Control Mounjaro lowers HbA1c levels significantly. Clinical studies show an average HbA1c reduction of 1.8% to 2.4%, helping patients maintain stable glucose levels throughout the day. Read the full SURPASS trial results for detailed efficacy data.
Supports Weight Loss Mounjaro reduces appetite and slows gastric emptying, leading to an average weight reduction of 12–22% in clinical trials. This makes it one of the most effective treatments for weight management in Type 2 diabetes patients. See the SURMOUNT-1 trial data for full weight loss outcomes.
Once-Weekly Administration Convenient self-injection with a pre-filled pen once a week reduces the burden of daily medication, improving patient compliance and quality of life.
Dual Receptor Action By targeting both GLP-1 and GIP receptors, Mounjaro provides superior glycemic control compared to GLP-1-only treatments such as Semaglutide (Ozempic). Learn more about the mechanism of action at MedlinePlus.
Potential Cardiovascular Benefits Ongoing research suggests Mounjaro may help reduce the risk of cardiovascular events including heart attack and stroke in patients with Type 2 diabetes and cardiovascular risk factors.
Reduced Insulin Dependency Many patients on Mounjaro see a significant reduction in their need for insulin, simplifying their overall diabetes management regimen.
How Mounjaro Works
Mounjaro mimics the natural hormones GLP-1 and GIP to:
- Stimulate insulin release when blood sugar is elevated — reducing post-meal glucose spikes
- Slow gastric emptying — prolonging feelings of fullness and reducing calorie intake
- Reduce glucagon secretion — preventing the liver from releasing excess glucose into the bloodstream
- Activate GIP receptors — enhancing insulin sensitivity in fat and muscle tissue
- Support long-term metabolic health by improving the body’s natural response to blood sugar changes
For a detailed explanation of Tirzepatide’s mechanism, refer to the American Diabetes Association guidelines.
Mounjaro vs Ozempic — Key Differences
| Feature |
Mounjaro (Tirzepatide) |
Ozempic (Semaglutide) |
| Receptor Targets |
GLP-1 + GIP (dual) |
GLP-1 only |
| HbA1c Reduction |
Up to 2.4% |
Up to 1.8% |
| Average Weight Loss |
12–22% |
8–15% |
| Dosing |
Once weekly |
Once weekly |
| Administration |
Subcutaneous injection |
Subcutaneous injection |
| Available at A.K. Pharma |
Request Quote |
Request Quote |
Dosage and Administration
- Administration: Subcutaneous injection (under the skin) once per week
- Starting Dose: 2.5mg per week for the first 4 weeks
- Maintenance Dose: Gradually increased to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on individual response and tolerability
- Injection Sites: Abdomen, thigh, or upper arm — rotate injection sites each week
- Timing: Can be taken at any time of day, with or without food
Full dosing guidelines are available at Drugs.com Mounjaro Dosage.
Who Should Use Mounjaro
Mounjaro is prescribed for:
- Adult patients with Type 2 diabetes who need better blood sugar control
- Patients with Type 2 diabetes who are overweight or obese and require weight management support
- Patients who have not achieved adequate glycemic control with other diabetes medicines
- Patients whose endocrinologist or diabetologist has recommended a GLP-1/GIP receptor agonist
Mounjaro is prescribed by endocrinologists, diabetologists, and general physicians. A.K. Pharma supplies Mounjaro to hospitals, diabetes clinics, and pharmacies serving these specialists across India.
Possible Side Effects
Common side effects may include nausea, vomiting, diarrhea, constipation, and appetite reduction. These effects are generally mild to moderate and tend to improve over time as the body adjusts to the medication.
Less common but serious side effects include pancreatitis, gallbladder problems, low blood sugar (when used with insulin or sulfonylureas), kidney problems, and allergic reactions. Patients should consult their healthcare provider immediately if they experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction.
Full side effect information is available at FDA Mounjaro Safety Information.
Precautions
- Not approved for individuals with Type 1 diabetes or diabetic ketoacidosis
- Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Mounjaro
- Patients with a history of pancreatitis should consult a healthcare provider before use
- Those with kidney issues should discuss potential risks with their doctor
- Not recommended during pregnancy or breastfeeding
- Refer to WHO diabetes treatment guidelines for broader treatment context
Storage and Handling
- Store Mounjaro between 2°C and 8°C in a refrigerator
- Do not freeze
- Keep away from direct light and heat
- Once removed from refrigerator, it can be stored at room temperature (up to 30°C) for up to 21 days
- Do not use if the solution is cloudy, discoloured, or contains particles
A.K. Pharma ensures all cold chain requirements are maintained during storage and supply of Mounjaro, guaranteeing the integrity and efficacy of every unit supplied.
Manufacturer Information
Mounjaro (Tirzepatide) is manufactured by Eli Lilly and Company, a leading global pharmaceutical company with over 140 years of experience in developing innovative medicines. Lilly received FDA approval for Mounjaro in May 2022. A.K. Pharma supplies only genuine Mounjaro sourced from authorized distributors, ensuring 100% product authenticity for every order.
Related Diabetes Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Mounjaro used for? Mounjaro (Tirzepatide) is used to improve blood sugar control in adults with Type 2 diabetes. It is taken as a once-weekly subcutaneous injection as an adjunct to diet and exercise. More information is available at MedlinePlus.
Q. What is the generic name of Mounjaro? The generic name of Mounjaro is Tirzepatide. It belongs to the class of dual GIP and GLP-1 receptor agonists.
Q. Is Mounjaro available in India? Mounjaro can be supplied to hospitals, clinics, and pharmacies in India through licensed pharmaceutical distributors. Contact A.K. Pharma for availability and pricing.
Q. How is Mounjaro different from Ozempic? Mounjaro targets both GLP-1 and GIP receptors while Ozempic targets only GLP-1. The SURPASS-2 clinical trial showed Mounjaro achieves greater HbA1c reduction and more significant weight loss compared to Ozempic.
Q. What is the price of Mounjaro in India? Mounjaro price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Mounjaro from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. What strengths of Mounjaro are available? Mounjaro is available in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg pre-filled injection pens.
Q. Does A.K. Pharma supply Mounjaro in bulk? Yes. A.K. Pharma supplies Mounjaro in bulk to hospitals, nursing homes, diabetes clinics, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Q. Where can I find clinical evidence for Mounjaro? The SURPASS clinical trial programme data is published in the New England Journal of Medicine. The FDA approval information is available at FDA.gov.
Why Order Mounjaro from A.K. Pharma?
- Licensed pharmaceutical distributor based in New Delhi
- 100% genuine medicines sourced from authorized suppliers
- Cold chain maintained throughout storage and delivery
- Bulk supply available for hospitals, clinics, and pharmacies
- Prompt response to all quote requests
- Serving healthcare professionals across Delhi NCR and India
Contact A.K. Pharma for Mounjaro Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
